Kintara Therapeutics Valuation
| KTRADelisted Stock | USD 6.30 0.14 2.17% |
At this time, the firm appears to be overvalued. Kintara Therapeutics secures a last-minute Real Value of $5.67 per share. The latest price of the firm is $6.3. Our model forecasts the value of Kintara Therapeutics from analyzing the firm fundamentals such as Return On Equity of -3.71, current valuation of 17.98 M, and Shares Owned By Insiders of 0.12 % as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Kintara Therapeutics' price fluctuation is risky at this time. Calculation of the real value of Kintara Therapeutics is based on 3 months time horizon. Increasing Kintara Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Kintara Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Kintara Stock. However, Kintara Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 6.3 | Real 5.67 | Hype 6.22 |
The real value of Kintara Stock, also known as its intrinsic value, is the underlying worth of Kintara Therapeutics Company, which is reflected in its stock price. It is based on Kintara Therapeutics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Kintara Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Kintara Therapeutics helps investors to forecast how Kintara stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Kintara Therapeutics more accurately as focusing exclusively on Kintara Therapeutics' fundamentals will not take into account other important factors: Kintara Therapeutics Total Value Analysis
Kintara Therapeutics is now projected to have valuation of 17.98 M with market capitalization of 11.99 M, debt of 2.44 M, and cash on hands of 11.78 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Kintara Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
17.98 M | 11.99 M | 2.44 M | 11.78 M |
Kintara Therapeutics Asset Utilization
One of the ways to look at asset utilization of Kintara is to check how much profit was generated for every dollar of assets it reports. Kintara Therapeutics secures a negative usage of assets of -1.04 %, losing $0.0104 for each dollar of assets held by the firm. Inadequate asset utilization conveys that the company is being less effective with each dollar of assets it secures. Strictly speaking, asset utilization of Kintara Therapeutics shows how discouraging it operates for each dollar spent on its assets.Kintara Therapeutics Ownership Allocation
Kintara Therapeutics maintains a total of 55.66 Million outstanding shares. Roughly 98.41 % of Kintara Therapeutics outstanding shares are held by general public with 0.12 pct. owned by insiders and only 1.47 % by institutional investors. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.Kintara Therapeutics Profitability Analysis
Net Loss for the year was (8.32 M) with profit before overhead, payroll, taxes, and interest of 0.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Kintara Therapeutics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Kintara Therapeutics and how it compares across the competition.
About Kintara Therapeutics Valuation
The delisted stock valuation mechanism determines Kintara Therapeutics' current worth on a weekly basis. Our valuation model uses a comparative analysis of Kintara Therapeutics. We calculate exposure to Kintara Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Kintara Therapeutics's related companies.Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. Kintara Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California. Kintara Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 3 people.
Kintara Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 2.6 M |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Other Consideration for investing in Kintara Stock
If you are still planning to invest in Kintara Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kintara Therapeutics' history and understand the potential risks before investing.
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |